Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DN4.99 TCR-T cells
- Development stage
- Preclinical
- Lead developer
- IRCCS Ospedale San Raffaele
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
DN4.99 TCR-T cells are an experimental adoptive cell therapy consisting of human T cells engineered to express a T-cell receptor (TCR) specific for the lipid antigen methyl-lysophosphatidic acid (mLPA) presented by the monomorphic CD1c molecule. Developed by researchers at the San Raffaele Scientific Institute, this therapy targets hematological malignancies such as acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL). Unlike traditional MHC-restricted TCR-T therapies, DN4.99 targets CD1c, which is non-polymorphic, potentially allowing for a "universal" donor-unrestricted application across different patients without the need for HLA matching. Preclinical studies demonstrate that these cells selectively kill leukemia blasts while sparing normal CD1c-expressing cells like B cells and monocytes, due to the high enrichment of mLPA in malignant cells.
- Other names
- mLPA-specific TCR-T cellsCD1c-restricted TCR-T cellsCD-1c-restricted TCR-T cellsCD 1c-restricted TCR-T cells
02
Targets
CD1c-presented methyl-lysophosphatidic acid complex
Beyond the preview
Go deeper on DN4.99 TCR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DN4.99 TCR-T cells.